Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Pfizer Investigational Site
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Pfizer Investigational Site
-
Heidelberg, Victoria, Australia, 3084
- Pfizer Investigational Site
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4M1
- Pfizer Investigational Site
-
-
-
-
-
Villejuif Cedex, France, 94805
- Pfizer Investigational Site
-
-
-
-
-
Thessaloniki, Greece, 564 03
- Pfizer Investigational Site
-
-
-
-
-
Milano, Italy, 20133
- Pfizer Investigational Site
-
Milano, Italy, 20141
- Pfizer Investigational Site
-
-
-
-
Gld
-
Nijmegen, Gld, Netherlands, 6525 GA
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Singapore, 308433
- Pfizer Investigational Site
-
-
-
-
-
Lund, Sweden
- Pfizer Investigational Site
-
Stockholm, Sweden
- Pfizer Investigational Site
-
-
-
-
-
St. Gallen, Switzerland, CH-9007
- Pfizer Investigational Site
-
-
-
-
-
Leeds, United Kingdom, LS9 7TF
- Pfizer Investigational Site
-
London, United Kingdom, SW3 6JJ
- Pfizer Investigational Site
-
London, United Kingdom, NW1 2PG
- Pfizer Investigational Site
-
Newcastle-Upon-Tyne, United Kingdom, NE4 6BE
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35294
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35233-2115
- Pfizer Investigational Site
-
-
California
-
Los Angeles, California, United States, 90095
- Pfizer Investigational Site
-
Los Angeles, California, United States, 90033
- Pfizer Investigational Site
-
San Francisco, California, United States, 94115
- Pfizer Investigational Site
-
San Francisco, California, United States, 94115-1705
- Pfizer Investigational Site
-
Santa Monica,, California, United States, 90404
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Pfizer Investigational Site
-
Boston, Massachusetts, United States, 02115
- Pfizer Investigational Site
-
Boston, Massachusetts, United States, 02215
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0843
- Pfizer Investigational Site
-
Detroit, Michigan, United States, 48201
- Pfizer Investigational Site
-
Farmington Hills, Michigan, United States, 48334
- Pfizer Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455-0392
- Pfizer Investigational Site
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Pfizer Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131-0001
- Pfizer Investigational Site
-
Albuqurque, New Mexico, United States, 87106
- Pfizer Investigational Site
-
-
New York
-
New York, New York, United States, 10021
- Pfizer Investigational Site
-
New York, New York, United States, 10032
- Pfizer Investigational Site
-
New York, New York, United States, 10022
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Pfizer Investigational Site
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Pfizer Investigational Site
-
-
Tennessee
-
Franklin, Tennessee, United States, 37067
- Pfizer Investigational Site
-
Gallatin, Tennessee, United States, 37066
- Pfizer Investigational Site
-
Hermitage, Tennessee, United States, 37076
- Pfizer Investigational Site
-
Lebanon, Tennessee, United States, 37087
- Pfizer Investigational Site
-
Murfreesboro, Tennessee, United States, 37130
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37203
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37232
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37205
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37207
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37211
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37212
- Pfizer Investigational Site
-
Smyrna, Tennessee, United States, 37167
- Pfizer Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75246
- Pfizer Investigational Site
-
Houston, Texas, United States, 77030-4009
- Pfizer Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Prior SU011248 Protocol.
- Eligible to continue SU011248 treatment.
Exclusion Criteria:
- Uncontrolled CNS metastasis.
- Unfit to receive SU011248.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Sunitinib
|
Sunitinib dose varies according to the doses allowed in previous protocol.
It is given once a day, orally with various schedules depending on the parent protocol
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Duration of Treatment
Time Frame: Baseline up to Day 28 after last dose of study treatment
|
Baseline up to Day 28 after last dose of study treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A6181030
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.